Pluristem Therapeutics, Inc. (PSTI)
(Delayed Data from NSDQ)
$0.65 USD
+0.01 (1.27%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.65 USD
+0.01 (1.27%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal
by Zacks Equity Research
Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
by Zacks Equity Research
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Are Options Traders Betting on a Big Move in Pluristem Therapeutics (PSTI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Pluristem Therapeutics (PSTI) stock based on the movements in the options market lately.
Pluristem Completes Enrollment in Phase I Hematology Study
by Zacks Equity Research
Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.
Has Pluristem Therapeutics (PSTI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PSTI) Outperforming Other Medical Stocks This Year?
Is Pluristem Therapeutics (PSTI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PSTI) Outperforming Other Medical Stocks This Year?
Pluristem Therapeutics Inc. (PSTI) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. (PSTI).
Here's Why Momentum Investors Will Love Pluristem (PSTI)
by Zacks Equity Research
Does Pluristem (PSTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Pluristem Therapeutics (PSTI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PSTI) Outperforming Other Medical Stocks This Year?
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient
by Zacks Equity Research
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Implied Volatility Surging for Pluristem (PSTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pluristem (PSTI) stock based on the movements in the options market lately.
Pluristem Therapeutics Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Pluristem Therapeutics.
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Pluristem Therapeutics Inc. (PSTI) has been struggling lately, but the selling pressure may be coming to an end soon.
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
by Zacks Equity Research
Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.
Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Pluristem Therapeutics Inc. (PSTI) saw its shares rise over 5% on the day.
Pluristem's Ischemia Candidate Gets Fast Track Designation
by Zacks Equity Research
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
Pluristem Therapeutics (PSTI) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. (PSTI).
Pluristem (PSTI) Intermittent Claudication Study Enrolled
by Zacks Equity Research
Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.